On July 13, 2012, Medicinal Economic Newspaper published the list of “Top 100 Pharmaceutical Enterprises in China in 2011”. Fosun Pharma was once again among the list, ranking the 19th. At the same time, as it was the first time to select top pharmaceutical enterprises with creativity in China in 2011 from the list of top 100 pharmaceutical enterprises, Fosun Pharma was successfully elected as one of “Top 10 Pharmaceutical Enterprises with Creativity in China”.

The list of “Top 100 Pharmaceutical Enterprises in China in 2011” was initiated by the Southern Medicine Economic Research Institute of the State Food and Drag Administration (SFDA) in 2006. So far, it has been published for 7 successive years. Fosun Pharma participated in the election for 2 successive years and was rated among the list in both years, with a ranking gradually moving forward.

After years of development, Fosun Pharma has achieved rapid growth in its pharmaceutical business. In 2011, Fosun Pharma input 3100 million RMB into R&D. Last year, the company had a total of 118 new drugs and vaccines under development and 9 categories with a sales volume reaching 100 million RMB in disease treatment areas, including metabolism and alimentary canal, cardiovascular system, central nerve system, blood system and anti-infection. Combined with its own advantages, Fosun Pharma also started to integrate resources home and abroad innovatively to quickly obtain creative products and transform from low-end in the industrial chain to high end by making use of the advantages that international companies have in products and technology.

The rating was based on annual sales volumes of the enterprises through medicine manufacturing (in accordance with the Chinese accounting standards) in 2011. Enterprises participating in the rating should be pharmaceutical enterprises that were registered in China (excluding those that were registered in Hong Kong, Macro and Taiwan, and international pharmaceutical enterprises’ subsidiaries in China) and specialize in medicine manufacturing.

According to the sponsor, in order to better promote and encourage the development of national industry, and offer maximal attention and support, the committee of “Top 100 Pharmaceutical Enterprises” of the pharmaceutical industry determined to adjust the publication form of the ratings in 2011, the first year of the 12th Five-year Plan period, by just publishing the list of “Top 100 National Pharmaceutical Enterprises in China”. International pharmaceutical enterprises’ subsidiaries in China shall be published separately.